title: Exendins and exendin analogs for diabetic therapy: a patent review (2012-2015).
abstract: BACKGROUND
  Since exendin-4 (exenatide) was approved for diabetes therapy in 2005, several exendin analogs have been developed for the treatment of type 2 diabetes mellitus. As exenatide is a relatively short-acting injectable agent, major approaches have focused on developing long-acting exendin analogs to improve patient compliance and convenience.
  
  
  METHODS
  In this review, the authors report on patents related to exendins and exendin analogs from 2012 to 2015. The patents have been divided into three categories based on the technologies used to develop the new chemical entities: 1) chemical bioconjugate analogs; 2) recombinant fusion protein analogs; and 3) multifunctional peptide analogs.
  
  
  CONCLUSIONS
  Recently, research on exendins and their analogs has grown significantly, leading to the development of long-acting analogs and multifunctional peptides. While long-acting injectable agents are still the major products in the pharmaceutical industry, a significant growth is expected in the development of orally available exendins.
authors.affiliation: a College of Pharmacy and Research Institute of Pharmaceutical Sciences , Kyungpook National University , Daegu , Republic of Korea.
authors.forename: Eun Ji
authors.initials: EJ
authors.lastname: Park
authors.affiliation: b Drug Targeting Laboratory, College of Pharmacy , SungKyunKwan University , Suwon , Republic of Korea.
authors.forename: Sung Mook
authors.initials: SM
authors.lastname: Lim
authors.affiliation: b Drug Targeting Laboratory, College of Pharmacy , SungKyunKwan University , Suwon , Republic of Korea.
authors.forename: Kang Choon
authors.initials: KC
authors.lastname: Lee
authors.affiliation: a College of Pharmacy and Research Institute of Pharmaceutical Sciences , Kyungpook National University , Daegu , Republic of Korea.
authors.forename: Dong Hee
authors.initials: DH
authors.lastname: Na
mesh_terms: D000818:Animals; D003692:Delayed-Action Preparations; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy* / Q000503:physiopathology; D015195:Drug Design; D000077270:Exenatide; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D055118:Medication Adherence; D010330:Patents as Topic; D010455:Peptides / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology; D014688:Venoms / Q000008:administration & dosage* / Q000737:chemistry / Q000494:pharmacology
chemical_list: D003692:Delayed-Action Preparations; D007004:Hypoglycemic Agents; D010455:Peptides; D014688:Venoms; D000077270:Exenatide
keywords: Diabetes; exendin analogs; exendins; glucagon-like peptide-1 receptor agonists; incretin mimetics